跳至主要内容
MedPath Trial Home
临床试验
产品
机构
资讯
AI 研究
价格
Search
EN
登录
我们重视您的隐私
我们使用 Cookie 分析网站流量并改善您的体验。请参阅我们的
隐私政策
。
拒绝
接受
找到 485 条关于
“MANIFEST IO”
全部
485
临床试验
126
药物
52
机构
3
资讯
304
上个月
MANIFEST IO Launches Landmark UK-Wide Prospective Study to Unravel Immunotherapy Response and Toxicity
2年前
Comparing Long-Term Data for IO/IO and IO/TKI in Favorable-Risk Metastatic Renal Cell Carcinoma
去年
Nivolumab Plus Ipilimumab Shows Durable Survival Benefit in Advanced RCC
去年
MANIFEST Project Aims to Personalize Immunotherapy Through Biomarker Analysis
去年
IMU Biosciences Joins MANIFEST Consortium to Advance Cancer Immunotherapy Research
去年
IO Biotech Faces Nasdaq Delisting Risk Despite Promising Cancer Vaccine Advances
去年
IO Biotech Phase 3 Trial Fails to Meet Primary Endpoints
去年
IO-202 Plus Azacitidine Shows Promise in Treating CMML
2年前
ESMO 2024: Optimizing Post-IO Therapy in Clear Cell and Expanding Options for Non-Clear Cell RCC
去年
IO Biotech's Cylembio Cancer Vaccine Misses Primary Endpoint in Phase 3 Melanoma Trial
第 1 页,共 31 页
上一页
下一页